Roche Advances New Weight Loss Drug After Promising Trial Results
Roche AG has reported strong results from a mid-stage clinical trial of its experimental weight loss drug, CT-388, showing that study subjects lost an average of 22.5% of their body weight after 48 weeks of observation. Based on these findings, the company plans to move the drug into large Phase 3 trials later this year.
